New hope for sickle cell patients: drug access opens to prevent painful crises
NCT ID NCT03720626
Summary
This program provides eligible sickle cell disease patients with access to an investigational drug called crizanlizumab. The goal is to help prevent or reduce the frequency of painful vaso-occlusive crises (VOCs) in patients aged 12 and older who continue to experience these crises despite being on other preventive therapies. It is a managed access program, not a traditional clinical trial, designed to make the drug available to patients who may benefit while it undergoes further regulatory review.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.